Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

<p><span>The most innovative startup in health and life sciences in Europe at BioFit, 2020</span></p>

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-10-09 00:00:00

StemSight joins Endless Frontier Labs 2026-27 cohort

StemSight has been selected to join the Endless Frontier Labs’ 2026-27 cohort alongside 99 other ground-breaking companies! We look forward to working with EFL mentors, NYU Stern MBA students, and the rest of the companies selected for the Life Sciences track over the next 9 months.

 

2026-08-17 00:00:00

Life Science Leader article

In a new Life Science Leader guest column, StemSight CEO Laura Koivusalo discusses how the biotech industry's traditional risk-sharing model is evolving. The article highlights the growing need for stronger collaboration ecosystems to advance the next generation of regenerative medicines.

2026-06-16 00:00:00

StemSight granted patent in Singapore

StemSight has been granted a patent in Singapore, and received a notice of patent allowance in Canada and Japan. With the first patent now granted for the novel product, StemSight is entering an important growth phase as we prepare for Series A financing and future clinical development. Read the full press release here.

2026-04-13 00:00:00

New CheckOrphan article featuring StemSight

Our Chief Commercial Officer Ross Macdonald shares insights in a recent CheckOrphan interview on how StemSight's technology aims to cure limbal stem cell deficiency. Read the full piece to learn more about the future of regenerative eye therapies.

More News

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

CONTACT US

Subscribe to our newsletter

Subscribe now

Supported by:

Co-funded by: